A method for regulating β-amyloid protein aggregation based on circularly polarized light and its application

By combining SiO2-coated chiral optically active nanostructures with upconversion luminescent nanoparticles, and using circularly polarized light to interfere with the β-sheet conformation of β-amyloid protein, the problems of low selectivity for β-amyloid protein aggregation and drug toxicity in existing technologies are solved, achieving a highly efficient and safe treatment effect for Alzheimer's disease.

CN121015904BActive Publication Date: 2026-05-26CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY CHINESE ACADEMY OF SCIENCES
2 Cites 0 Cited by

Patent Information

Application Number
CN202511014311.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-07-23
Publication Date
2026-05-26
Estimated Expiration
2045-07-23

AI Technical Summary

Technical Problem

Existing technologies are ineffective in preventing the aggregation of β-amyloid (Aβ), and existing strategies have low selectivity and drug toxicity.

Method used

By combining SiO2-coated chiral optically active nanostructures with amino-modified upconversion luminescent nanoparticles, the β-sheet conformation is interfered with by circularly polarized light. The upconversion chiral nanomaterials are excited by 800–1400 nm laser light to emit circularly polarized light, thereby inhibiting the aggregation of β-amyloid protein.

Benefits of technology

It achieves efficient and safe inhibition of β-amyloid protein aggregation, improves Alzheimer's disease-related cognitive function, and has reversibility and high spatial selectivity, making it suitable for different protein aggregation systems.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This invention discloses a method for regulating β-amyloid protein aggregation based on circularly polarized light and its application. The method includes electrostatically binding an amino-modified upconversion luminescent nanoparticle to a SiO2-coated chiral optically active nanostructure to obtain an upconversion chiral nanomaterial; coating the surface of the upconversion chiral nanomaterial with a biocompatible coating and a brain-targeting ligand, then mixing it with β-amyloid protein, and targeting the region with 5–100 mW / cm² light. 2 Irradiation with an 800–1400 nm laser for 15–30 min excites upconversion chiral nanomaterials to emit circularly polarized light. This circularly polarized light inhibits the aggregation of β-amyloid protein by interfering with the formation of its β-sheet conformation. This invention utilizes circularly polarized light (CPL) to induce changes in key protein site interactions, thereby altering the conformation of protein aggregation. This process is reversible and highly spatially selective. Animal experiments have verified that this method can effectively block Aβ aggregation and improve cognitive function.
Need to check novelty before this filing date? Find Prior Art